Long-Term Outcome of Patients with AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Long-Term Outcome of Patients with AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation

key information

source: Blood

year: 2015

authors: Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC

summary/abstract:

In immunoglobulin light chain (AL) amyloidosis, amyloid fibril deposits, derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia, accumulate in extracellular tissues and damage vital organs. High-dose melphalan and autologous stem cell transplantation (HDM/SCT) have been shown to induce both hematologic and clinical remissions in selected patients with AL amyloidosis, and it prolongs survival substantially when hematologic remissions are achieved.

We report on the outcome for AL amyloidosis patients treated with HDM/SCT for a >20-year period to address remission durability and long-term results. We previously reported on our experience of 312 patients treated with HDM/SCT in 2004, and this series was updated in Blood in 2011 with 421 patients.

organization: Boston University School of Medicine, USA; Boston University School of Public Health, USA

DOI: 10.1182/blood-2015-08-662726

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close